Janus kinase inhibitors – a new effective treatment option for refractory isolated non-infectious ocular inflammatory disordersVidic Krhlikar, Nina (Avtor) Tomšič, Matija (Avtor) Jaki Mekjavić, Polona (Avtor) Klobučar, Pia (Avtor) Bregar, Janez (Avtor) Šurlan Popović, Katarina (Avtor) Vidović Valentinčič, Nataša (Avtor) Janus kinase inhibitorsnon-infectious ocular inflammationuveitisThe Janus kinase (JAK) pathway regulates inflammatory responses, with dysregulation implicated in various autoimmune disorders, including non-infectious orbital or ocular inflammation. While corticosteroids are commonly used, their long-term use is limited by side effects. Janus kinase inhibitors (JAK-i) present an emerging therapeutic option. This study systematically reviewed the effectiveness and safety of JAK-i in managing isolated non-infectious ocular inflammation. A comprehensive literature review utilizing MEDLINE/PubMed, Cochrane and Web of Science search identified studies reporting isolated non-infectious ocular inflammation cases treated with JAK-i up to May 2025. Search terms combined JAK-i keywords with ocular inflammation terms. Among 21 isolated non-infectious ocular inflammation cases treated with JAK-i, tofacitinib was predominant. Most patients received JAK-i after disease-modifying antirheumatic drug therapy, with additional corticosteroid usage. Ocular inflammation was successfully controlled in 21 out of 21 patients, with one case of herpetic keratitis necessitating additoinal systemic virostatics. JAK-i show promise as an effective option for refractory isolated non-infectious ocular inflammation. However, further research is warranted with longer follow-up periods. Safety concerns underline the importance of personalized risk-benefit assessments in JAK-i therapy. While limitations exist, this review supports the potential of JAK-i use in managing isolated non-infectious ocular inflammation.20262026-05-04 08:49:24Neznano29240sl